A study recently published in JAMA Network Open found that nearly one-third of sole-source, off-patent, and off-exclusivity drug products saw major increases in drug prices over any calendar year.
In...
FDA recently issued an emergency use authorization (EUA) to Yale School of Public Health for its SalivaDirect COVID-19 test.
For more coronavirus updates, visit our resource page, updated twice...
AstraZeneca recently announced an agreement with the European Commission (EC) to supply up to 400 million doses of its COVID-19 vaccine, AZD122.
For more coronavirus updates, visit our resource...
When asked if they would get an FDA-approved and affordable COVID-19 vaccine, 65 percent of Americans answered that they would, while 35 percent would not, according to a recent Gallup survey.
For...
Pfizer recently announced a multi-year agreement with Gilead Sciences to manufacture and supply the company’s investigational COVID-19 treatment, remdesivir.
For more coronavirus updates, visit...
Eli Lilly and Company recently announced the initiation of a Phase 3 trial, BLAZE-2, studying potential COVID-19 antibody treatment in residents and staff at nursing facilities across the US.
For more...
Johnson & Johnson recently announced that its lead COVID-19 vaccine candidate protected against SARS-CoV-2 infection in pre-clinical studies using monkeys.
For more coronavirus updates, visit...
GSK and Sanofi reached an agreement with the UK government for the supply of up to 60 million doses of the company’s jointly developed COVID-19 vaccine.
For more coronavirus updates, visit...
Experts believe that the next generation of cell and gene therapies holds significant promise for patients because this alternative treatment option represents an advancement in personalized...
Thermo Fisher Scientific and Lyell Immunopharma recently partnered to develop manufacturing processes create more effective cell therapies to benefit cancer patients.
The companies main goal is to...
Pfizer and BioNTech recently announced the start of a global (excluding China) Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA COVID-19 vaccine...
A recent Health Affairs study suggested that a “pull funding” program that incentivizes late-stage development for COVID-19 vaccine development may combat challenges with speed, scale,...
The Trump administration is aiming to lower drug prices by eliminating kickbacks to middlemen, like pharmacy benefit managers (PBMs), and increasing drug importation in three new executive orders...
Direct-acting antivirals (DAA) could be the answer in treating patients with hepatitis C viral (HCV) infections, regardless of whether they also suffer from cirrhosis, according to a JAMA Network Open...
HHS and the Department of Defense (DoD) recently announced an agreement with Pfizer Inc. for large-scale production and nationwide delivery of 100 million doses of its COVID-19 vaccine in the US.
For...
GSK and CureVac recently announced a collaboration for the research, development, manufacturing, and commercialization of five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious...
A recent clinical trial found that a new COVID-19 vaccine candidate, ChAdOx1 nCoV-19, given as a single dose was safe and well tolerated, according to a new study published in Lancet.
For more...
Eli Lilly and Company recently announced that its monoclonal antibody, mirikizumab, showed promise in its Phase 3 study for patients with moderate to severe plaque psoriasis.
Mirikizumab is a...
In patients with Alzheimer’s disease, a daily dose of dopamine agonist, rotigotine, showed no significant benefit from baseline to 24 weeks when compared with a placebo, according to a JAMA...
Roche and Blueprint Medicines Corporation recently signed an agreement to provide exclusive rights to Roche for global co-development and commercialization of an investigational therapy for patients...
